EYPT vs. TXG, TRNS, ALNT, LAB, CTKB, SENS, QSI, AEHR, MASS, and QTRX
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Aehr Test Systems (AEHR), 908 Devices (MASS), and Quanterix (QTRX). These companies are all part of the "measuring and control equipment" industry.
EyePoint Pharmaceuticals vs. Its Competitors
10x Genomics (NASDAQ:TXG) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings.
10x Genomics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
10x Genomics presently has a consensus target price of $15.81, indicating a potential upside of 46.64%. EyePoint Pharmaceuticals has a consensus target price of $25.38, indicating a potential upside of 188.02%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than 10x Genomics.
10x Genomics has a net margin of -29.90% compared to EyePoint Pharmaceuticals' net margin of -226.57%. 10x Genomics' return on equity of -25.40% beat EyePoint Pharmaceuticals' return on equity.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. 9.4% of 10x Genomics shares are held by insiders. Comparatively, 4.5% of EyePoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
EyePoint Pharmaceuticals has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, EyePoint Pharmaceuticals had 4 more articles in the media than 10x Genomics. MarketBeat recorded 10 mentions for EyePoint Pharmaceuticals and 6 mentions for 10x Genomics. EyePoint Pharmaceuticals' average media sentiment score of 1.14 beat 10x Genomics' score of 0.31 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the news media.
EyePoint Pharmaceuticals received 405 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 70.40% of users gave EyePoint Pharmaceuticals an outperform vote while only 50.00% of users gave 10x Genomics an outperform vote.
Summary
EyePoint Pharmaceuticals beats 10x Genomics on 11 of the 18 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EYPT) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy EYPT Stock Free EYPT Stock Alerts